VJHemOnc is committed to improving our service to you

EHA 2020 | Melflufen for myeloma: HORIZON

VJHemOnc is committed to improving our service to you

Paul Richardson

Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, reports updates from the HORIZON study (NCT02963493), which is investigating the benefit of melflufen in combination with dexamethasone in relapsed/refractory multiple myeloma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter